Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma

Lung adenocarcinoma or non-small cell lung cancer (NSCLC) represents one of the most diagnosed cancers worldwide. Anaplastic lymphoma kinase (ALK) mutation, a tyrosine kinase and ALK fusion or rearrangement oncogene, has been found rarely in patients with NSCLC. Newer treatment modalities with diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashish, Sethi, Rodriguez, Robin R, Sethi, Purva, Yu, Fang, Raj, Moses
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633320/
https://www.ncbi.nlm.nih.gov/pubmed/36348885
http://dx.doi.org/10.7759/cureus.29922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633320/
https://www.ncbi.nlm.nih.gov/pubmed/36348885
http://dx.doi.org/10.7759/cureus.29922

Ejemplares similares